Peri-implantitis Market Outlook 2031
The global peri-implantitis market size was USD 911.90 Million in 2022 and is expected to reach USD 1.93 Billion by 2031 expanding at a CAGR of 8.7% during the forecast period, 2023-2031. Peri-implantitis is a contagious disease that causes soft tissue inflammation and bone deterioration near the function of an Osseo integrated implant. Dental implants are an attempted therapy for replacing damaged teeth in a medical surgical.
The most common symptoms of peri-implantitis include severe toothache, gum pain, the sensation that the implant is loose, and irritation Smoking, poor oral hygiene, a history of periodontitis, biomechanical overload that leads to high stress and micro-fractures causing loss of osseointegration around the neck of the implant, poor quality bone, incorrect implant position, implant overloading, and diabetes are all major risk factors for peri-implantitis.
Peri-implantitis is categorized into four stages based on the amount of bone loss in the implanted teeth. The dentist determines the treatment aim based on the degree of osseous involvement, which includes halting disease development, regeneration, and replacement.
Peri-implantitis Market Trends, Drivers, Restraints, and Opportunities
- Growing demand for dental implants, and increased awareness of diseases associated with dental implants are major factors expected to drive the growth of the peri-implantitis market.
- Technological advancements is estimated to propel the growth of the market. For instance, mechanical debridement combined with laser decontamination, surgical debridement with guided bone regeneration (GBR) for bony and soft-tissue repair, and diagnostic genetic biomarker approaches have improved clinical results and selective calculus removal.
- Lack of information, high surgical costs, and government regulation situations are some of the factors that are expected to restrain demand growth during the forecast period.
- Increasing incidence of oral disorders is anticipated to spur the market growth in the projected timeline.
Scope of Peri Implantitis Market Report
The report on the global peri-implantitis market includes an assessment of the market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast.
|
Attributes
|
Details
|
|
Report Title
|
Peri-implantitis Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Method Types (Surgical [Bone Regeneration, Open Flap Debridement, and Implantoplasty] and Non-surgical [Mechanical Debridement, Laser Debridement, Antibiotics, and Others]), End-Users (Hospitals, Dental Clinics, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Geistlich Pharma Inc., R.N, Laboratories Pvt. Ltd.; Basic Pharma Life Science pvt ltd., Cadila Pharmaceuticals, Prachi Pharmaceuticals Private limited, Pfizer Inc., Healthy Life Pharma
|
Peri-implantitis Market Segment Insights
Surgical segment to constitute a significant market share
On the basis of method types, the market can be bifurcated into surgical and non-surgical. The surgical segment can be further segmented into bone regeneration, open flap debridement, and implantoplasty. The non-surgical segment can be sub-segmented into mechanical debridement, laser debridement, antibiotics, and others.
The surgical segment is anticipated to hold a large market share during the forecast period. Surgical method provides extensive debridement and cleaning of the damaged implant. This approach is regarded as the gold standard for treating peri-implantitis. The bone regeneration sub-segment, commonly known as resective surgery, is expected to grow at a robust rate during the forecast period owing to the technique's favorable treatment outcomes in the treatment of peri-implantitis around implants.
The laser debridement sub-segment is expected to exhibit a high CAGR during the forecast period, as lasers can easily address small portions of the implant surface that mechanical methods cannot reach. Er:YAG (Erbium-Doped Yttrium Aluminum Garnet), CO2 (Carbon Dioxide Laser), and diode lasers clinically significant reduces pocket-probing depth and increases clinical attachment level, as well as full bacterial elimination. These non-surgical procedures are gaining preference as they are non-invasive, require shorter recovery time, and have fewer problems.
Dental clinics segment is expected to hold a large market share
In terms of end-users, the market can be segmented into hospitals, dental clinics, and others. The dental clinics segment is estimated to account for a major market share during the forecast period. Rising preference among patients for clinics owing to high-quality care is driving the segment growth.
Europe estimated to dominate the market
Based on regions, the market can be classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Europe is anticipated to dominate the market due to increasing patient population with periodontal diseases, technical breakthroughs, and expanding public awareness regarding dental implants and related disease.
Dental implants and related therapies are covered by European National Health Services for individuals suffering from serious periodontal diseases that impair the supporting structures of teeth.
Segments
By Method Types
- Surgical
- Bone Regeneration
- Open Flap Debridement
- Implantoplasty
- Non-Surgical
- Mechanical Debridement
- Laser Debridement
- Antibiotics
- Others
By End-Users
- Hospitals
- Dental Clinics
- Others
By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
By Key Players
Competitive Landscape
The key players of the market includes Geistlich Pharma Inc., R.N, Laboratories Pvt. Ltd.; Basic Pharma Life Science pvt ltd., Cadila Pharmaceuticals, Prachi Pharmaceuticals Private limited, Pfizer Inc., Healthy Life Pharma.
One of the key factors boosting market participants' competition is the rapid growth of technology in the development of anti-infective medications and treatments. Furthermore, several corporations are collaborating to develop pharmaceuticals in order to get their products to market faster.
- For instance, in January 2017, Pfizer invested around USD 1.0 billion for the development and commercialization rights to AstraZeneca's small molecule anti-invectives business, largely outside the US.
Request For Customization
Enquiry Before Buying
Speak With Analyst
